MedTrace Logo

A Study of JMT101 in Patients With Metastatic Colorectal Cancer

NCT06089330 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 102

Last updated 2023-10-18

No results posted yet for this study

Summary

This study is a phase Ⅱ, randomized, controlled, open-label, multi-center study with safety run-in to evaluate the efficacy and safety of JMT101 combined with Irinotecan and SG001 in Patients with Metastatic Colorectal Cancer (mCRC).

Conditions

  • Metastatic Colorectal Cancer (mCRC)

Interventions

DRUG

JMT101

JMT101, 6 mg/kg, IV infusion once every two weeks (one treatment cycle is 4 weeks).

DRUG

SG001

240 mg, IV infusion once every two weeks (one treatment cycle is 4 weeks).

DRUG

Irinotecan

180mg/m\^2, IV infusion once every two weeks (one treatment cycle is 4 weeks).

DRUG

Regorafenib (Stivarga)

160 mg, taken orally once daily for the first 21 days of each 28-day cycle.

Sponsors & Collaborators

  • Shanghai JMT-Bio Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-31
Primary Completion
2024-07-31
Completion
2024-12-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06089330 on ClinicalTrials.gov